In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
The in vitro and in vivo antichlamydial activities of HSR-903 were investigated. The MICs of HSR-903 for different species of chlamydia were 0.016 to 0.063 microg/ml, which were superior to those of conventional fluoroquinolones. The therapeutic effect of HSR-903 in experimental mouse Chlamydia psittaci pneumonia was also excellent and almost equal to that of minocycline and superior to that of ofloxacin. These results indicate that HSR-903 may be useful in the treatment of respiratory infections caused by chlamydiae.
Niki
Y
Y
Department of Medicine, Kawasaki Medical School, Matsushima, Kurashiki, Japan.
Miyashita
N
N
Kubota
Y
Y
Nakajima
M
M
Matsushima
T
T
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002689:Chlamydia / Q000187:drug effects*; D002691:Chlamydophila psittaci / Q000187:drug effects*; D024841:Fluoroquinolones; D006367:HeLa Cells; D006801:Humans; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000627:therapeutic use; D015242:Ofloxacin / Q000627:therapeutic use; D009956:Psittacosis / Q000188:drug therapy* / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D015242:Ofloxacin; D008911:Minocycline; C106426:olamufloxacin